Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
Recruiting in Palo Alto (17 mi)
+31 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Furiex Pharmaceuticals, Inc
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine the efficacy, safety and tolerability of JNJ-32729463 compared to moxifloxacin for the treatment of subjects requiring hospitalization for Community-Acquired Bacterial Pneumonia (CABP).
Research Team
Eligibility Criteria
Inclusion Criteria
women of childbearing potential must agree to use an acceptable method of birth control
clinical diagnosis of community acquired bacterial pneumonia (CABP)
PORT score of II or greater
See 2 more
Treatment Details
Interventions
- JNJ-32729463 (Antibiotic)
- Moxifloxacin (Antibiotic)
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: JNJ-32729463 Open-LabelExperimental Treatment1 Intervention
subjects with suspected or confirmed S. aureus CABP may be entered into an open-label JNJ 32729463 treatment group at selected study sites
Group II: JNJ-32729463Experimental Treatment1 Intervention
Group III: moxifloxacinActive Control1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Furiex Research SiteOrlando, FL
Furiex Research SiteVero Beach, FL
Furiex Research SiteSylmar, CA
Furiex Research SiteAnaconda, MT
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Furiex Pharmaceuticals, Inc
Lead Sponsor
Trials
6
Patients Recruited
3,700+